Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam short interfering RNA patent claims allowed
Based on research by Dr Thomas Tuschl, a founder of Alnylam, the newly allowed claims broadly cover methods of making siRNAs for any target, with or without chemical
Based on research by Dr Thomas Tuschl, a founder of Alnylam, the newly allowed claims broadly cover methods of making siRNAs for any target, with or without chemical
Although the bacteria has only been tested in a lab dish, HIV specialist Bharat Ramratnam and his colleagues from Brown Medical School assert that a modified version of
The company believes this significantly strengthens its intellectual property platform in order to develop and ultimately commercialize ZIO-101. “We are thrilled to have a very strong patent position
The Shanghai Institutes for Biological Sciences (SIBS) initial human clinical trial results indicate that T cell vaccination induces immune responses that correlate with reductions in joint swelling, tenderness,
Under the terms of the agreement, which is valid until the end of 2008, ChemGenex will receive a total retainer fee of approximately A$1 million, with potential additional
The terms of this expanded agreement include Squire making an up-front payment, providing on-going royalties on the sale of Pennsaid and making an investment of $500,000 in Nuvo.
The companies aim to jointly identify and develop pre-clinical development candidates suitable for future selection as drug candidates for clinical testing. While the original contract was exclusively targeted
The potential vaccine will be based on Tripep’s proprietary hepatitis C virus (HCV) antigen and delivered to infected individuals using Inovio’s medpulser DNA delivery system. Initiation of a
In order to achieve the milestone 4SC applied its proprietary virtual high throughput screening technology, 4Scan, to identify active agents against specific targets provided by Sanwa Kagaku Kenkyusho
UCB Bioproducts has been active in chemical peptide manufacturing for over 20 years. The division has approximately 300 employees located in Braine-l’Alleud just outside of Brussels, Belgium. By